Lee M L, Mankarious S, Ochs H, Fischer S, Wedgwood R J
Baxter Healthcare Corporation, Glendale, California 91203.
Immunol Invest. 1991 Apr;20(2):193-8. doi: 10.3109/08820139109050787.
The advent of immunoglobulin concentrates suitable for intravenous administration has greatly improved the clinical management of patients with a primary immunodeficiency syndrome. However, proper treatment requires understanding of the pharmacokinetics of the infused IgG and its components. We review here the work that has been conducted in this area. In particular, two studies have shown that these concentrates have adequate catabolic properties with regards to total IgG, IgG subclasses, and specific antibodies. We conclude that careful evaluation of the pharmacokinetics of a given IgG preparation is necessary in order to determine an appropriate treatment regimen.
